In vitro fertilization in the older patient

Current Women's Health Reports

Volumn 3, Issue 5, 2003, Pages 375-383

  Derman, Seth G ^a   Seifer, David B ^a  

^a Univ of Med Dent NJ Robert Wood   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOCHEMICAL MARKER; BUSERELIN; CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; INHIBIN B; LEUPRORELIN; MUELLERIAN INHIBITING FACTOR; NITRIC OXIDE DONOR; ORAL CONTRACEPTIVE AGENT; PEPTIDE HORMONE; RECOMBINANT FOLLITROPIN;

AGE; CELL COUNT; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG USE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; OOCYTE; OVARY FOLLICLE CELL; OVARY FUNCTION; OVULATION INDUCTION; PATIENT COUNSELING; PREGNANCY RATE; PROVOCATION TEST; REVIEW; SPONTANEOUS ABORTION; TREATMENT OUTCOME; ADULT; CORPUS LUTEUM; DRUG EFFECT; HIGH RISK PREGNANCY; MATERNAL AGE; METABOLISM; METHODOLOGY; OVARY FOLLICLE; STANDARD; UNITED STATES; WOMEN'S HEALTH;

ADULT; AGE FACTORS; CORPUS LUTEUM; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GROWTH HORMONE; HUMANS; INFERTILITY, FEMALE; MATERNAL AGE; OVARIAN FOLLICLE; PREGNANCY, HIGH-RISK; UNITED STATES; WOMEN'S HEALTH;

EID: 1542568314     PISSN: 15345874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. American Society for Reproductive Medicine Society for Assisted Reproductive Technology Registry: Assisted reproductive technology in the United States: 1999 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 2002, 78:918-931.
2. Seifer DB, Naftolin F: Moving toward an earlier and better understanding of perimenopause. Fertil Steril 1998, 69:387-388.
3. American Society for Reproductive Medicine Society for Assisted Reproductive Technology Registry: Assisted reproductive technology in the United States and Canada: 1994 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 1996, 66:697-705.
4. Munne S, Alikani M, Tomkin G, et al.: Embryo morphology, developmental rates, and maternal age are correlated with chromosome abnormalities. Fertil Steril 1995, 64:382-391.
5. Muasher SJ, Oehninger S, Simonetti S, et al.: The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988, 50:298-307.
6. Sharara FI, Scott RT Jr, Seifer DB: The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol 1998, 179(3 Pt 1):804-812.
7. Martin JS, Nisker JA, Tummon IS, et al.: Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril 1996, 65:1238-1240.
8. Khalifa E, Toner JP, Muasher SJ, Acosta AA: Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization. Fertil Steril 1992, 57:835-839.
9. Chuang CC, Chen CD, Chao KH, et al.: Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertil Steril 2003, 79:63-68.
10. László FJ, Bancsi MM, Broekmans FJM, et al.: Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003, 79:1091-1100.
11. van Rooij IA, Bancsi LF, Broekmans FJ, et al.: Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 2003, 3:482-488.
12. Lambalk CB: Value of elevated basal follicle-stimulating hormone levels and the differential diagnosis during the diagnostic subfertility work-up. Fertil Steril 2003, 79:489-490.
13. Toner JP: Age = egg quality, FSH LEVEL = egg quantity [comment]. Fertil Steril 2003, 79:491.
14. Licciardi FL, Liu HC, Rosenwaks Z: Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995, 64:991-994.
15. Smotrich DB, Widra EA, Gindoff PR, et al.: Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril 1995, 64:1136-1140.
16. Scott RT, Toner JP, Muasher SJ, et al.: Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989, 51:651-654.
17. Buyalos RP, Daneshmand S, Brzechffa PR: Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy. Fertil Steril 1997, 68:272-277.
18. Mukherjee T, Copperman AB, Lapinski R, et al.: An elevated day three follicle-stimulating hormone: luteinizing hormone ratio (FSH:LH) in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation. Fertil Steril 1996, 65:588-593.
19. Yamashita T, Ishimaru T, Fujishita A, et al.: Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in- vitro fertilization and embryo transfer programme. Hum Reprod 1996, 11:1615-1619.
20. Navot D, Rosenwaks Z, Margalioth EJ: Prognostic assessment of female fecundity. Lancet 1987, 2:645-647.
21. Tanbo T, Dale PO, Abyholm T, Stokke KT: Follicle-stimulating hormone as a prognostic indicator in clomiphene citrate/human menopausal gonadotropin-stimulated cycles for in vitro fertilization. Hum Reprod 1989, 4:647-650.
22. Loumaye E, Billion JM, Mine JM, et al.: Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test. Fertil Steril 1990, 53:295-301.
23. Scott RT, Leonardi MR, Hofmann GE, et al.: A prospective evaluation of clomiphene citrate challenge test screening of the general infertility population. Obstet Gynecol 1993, 82(4 Pt 1):539-544.
24. Hofmann GE, Danforth DR, Seifer DB: Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 1998, 69:474-477.
25. Seifer DB, Scott RT Jr, Bergh PA, et al.: Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril 1999, 72:63-65.
26. Seifer DB, Lambert-Messerlian G, Hogan JW, et al.: Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997, 67:110-114.
27. Fanchin R, Schonauer LM, Righini C, et al.: Serum anti-müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003, 18:328-332.
28. van Rooij IA, Broekmans FJ, te Velde ER, et al.: Serum anti-müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002, 17:3065-3071.
29. Seifer DB, MacLaughlin DT, Christian BP, et al.: Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002, 77:468-471.
30. Fanchin R, Schonauer LM, Righini C, et al.: Serum anti-müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003, 18:323-327.
31. Syrop CH, Willhoite A, Van Voorhis BJ: Ovarian volume: a novel outcome predictor for assisted reproduction. Fertil Steril 1995, 64:1167-1171.
32. Syrop CH, Dawson JD, Husman KJ, et al.: Ovarian volume may predict assisted reproductive outcomes better than follicle stimulating hormone concentration on day 3. Hum Reprod 1999, 7:1752-1756.
33. Sharara FI, McClamrock HD: Use of microdose GnRH agonist protocol in women with low ovarian volumes undergoing IVF. Hum Reprod 2001, 16:500-503.
34. Morris JL, Thayer AC, Soules MR, Klein NA: Antral follicle count by transvaginal ultrasound is reflective of the actual primordial follicle pool. Fertil Steril 2002, 78:S3-S4.
35. Scheffer GI, Broekmans FJM, Looman CWN, et al.: The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 2003, 18:700-706.
36. Chang MY, Chiang CH, Hsieh TT, et al.: Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998, 69:505-510.
37. Frattarelli JL, Lauria-Costab DF, Miller B, et al.: Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. Fertil Steril 2000, 74:512-517.
38. Chin KV, Seifer DB, Feng B, et al.: DNA microarray analysis of the expression profiles of luteinized granulosa cells as a function of ovarian reserve. Fertil Steril 2002, 77:1214-1218.
39. Seifer DB, DeJesus V, Hubbard K: Mitochondrial deletions in luteinized granulosa cells as a function of age in women undergoing in vitro fertilization. Fertil Steril 2002, 78:1046-1048.
40. van Hooff MH, Alberda AT, Huisman GJ, et al.: Doubling the human menopausal gonadotrophin dose in the course of an in vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993, 8:369-373.
41. Karande VC, Jones GS, Veeck LL, Muasher SJ: High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil Steril 1990, 53:486-489.
42. Land JA, Yarmolinskaya MI, Dumoulin JC, Evers JL: High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996, 65:961-965.
43. Hofmann GE, Toner JP, Muasher SJ, Jones GS: High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization. J In Vitro Fert Embryo Transf 1989, 6:285-289.
44. Crosignani PG, Ragni G, Lombroso GC, et al.: IVF: induction of ovulation in poor responders. J Steroid Biochem 1989, 32:171-173.
45. Al-Inany H, Aboulghar M, Mansour R, Serour G: Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod 2003, 18:305-313.
46. Raga F, Bonilla-Musoles F, Casan EM, Bonilla F: Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Hum Reprod 1999, 14:1431-1434.
47. De Placido G, Alviggi C, Mollo A, et al.: Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 2000, 15:17-20.
48. Rombauts L, Suikkari AM, MacLachlan V, et al.: Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle. Fertil Steril 1998, 69:665-669.
49. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J: Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003, 9:61-76.
50. Surrey ES, Bower J, Hill DM, et al.: Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril 1998, 69:419-424.
51. Leondires MP, Escalpes M, Segars JH, et al.: Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. Fertil Steril 1999, 72:1018-1023.
52. Akman MA, Erden HF, Tosun SB, et al.: Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001, 16:868-870.
53. Kotarba D, Kotarba J, Hughes E: Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2000, 2:CD000099.
54. Battaglia C, Salvatori M, Maxia N, et al.: Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Hum Reprod 1999, 14:1690-1697.
55. Lindheim SR, Barad DH, Witt B, et al.: Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. J Assist Reprod Genet 1996, 13:745-747.
56. Moreno C, Ruiz A, Simon C, et al.: Intracytoplasmic sperm injection as a routine indication in low responder patients. Hum Reprod 1998, 13:2126-2129.
57. Cohen J, Alikani M, Trowbridge J, Rosenwaks Z: Implantation enhancement by selective assisted hatching using zona drilling of human embryos with poor prognosis. Hum Reprod 1992, 7:685-691.
58. Schoolcraft WB, Schlenker T, Gee M, et al.: Assisted hatching in the treatment of poor prognosis in vitro fertilization candidates. Fertil Steril 1994, 62:551-554.